Johnson & Johnson stock: Is JNJ a good dividend stock?
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSE:JNJ gains 0.28% on Monday to outpace the broader markets on another bearish day.
- Johnson & Johnson continues to rebound from the widespread pause of its COVID-19 vaccine.
- The pharmaceutical conglomerate is set to announce Q1 earnings on April 20th
NYSE:JNJ has had an uncharacteristically eventful week after making global headlines following some rare side effects from its COVID-19 vaccine. On Monday, Johnson & Johnson actually gained 0.28% to close the first trading day of the week at $162.69, amidst another red day for the S&P 500. Shares of Johnson & Johnson have struggled over the past year, and although the stock remains above both its 50-day and 200-day moving averages, JNJ has lagged the S&P 500 index by over 40% during the past 52-weeks.
Stay up to speed with hot stocks' news!
Johnson & Johnson found themselves at the center of a global controversy last week, as its COVID-19 vaccine was reported to have caused a rare form of blood clots in six patients. The delivery of the vaccine was halted around the world, including in Europe, South Africa, and the United States. JNJ’s goal of 100 million vaccine deliveries to the United States by the end of May could be at risk now, although many believe that the FDA and CDC will soon lift the pause in order to continue towards attaining herd immunity. In all, only about one in every million doses of Johnson & Johnson’s vaccine resulted in the rare blood clots so far.
JNJ Stock dividend
Johnson & Johnson is set to report its Q1 earnings report on Tuesday, and investors have no reason to believe it won’t be another stellar quarter from one of the largest companies in the world. JNJ currently pays a generous 2.49% dividend yield to shareholders, and with over 50 consecutive years of the company raising its dividends, it represents one of the best long-term investments available to investors.
- NYSE:JNJ gains 0.28% on Monday to outpace the broader markets on another bearish day.
- Johnson & Johnson continues to rebound from the widespread pause of its COVID-19 vaccine.
- The pharmaceutical conglomerate is set to announce Q1 earnings on April 20th
NYSE:JNJ has had an uncharacteristically eventful week after making global headlines following some rare side effects from its COVID-19 vaccine. On Monday, Johnson & Johnson actually gained 0.28% to close the first trading day of the week at $162.69, amidst another red day for the S&P 500. Shares of Johnson & Johnson have struggled over the past year, and although the stock remains above both its 50-day and 200-day moving averages, JNJ has lagged the S&P 500 index by over 40% during the past 52-weeks.
Stay up to speed with hot stocks' news!
Johnson & Johnson found themselves at the center of a global controversy last week, as its COVID-19 vaccine was reported to have caused a rare form of blood clots in six patients. The delivery of the vaccine was halted around the world, including in Europe, South Africa, and the United States. JNJ’s goal of 100 million vaccine deliveries to the United States by the end of May could be at risk now, although many believe that the FDA and CDC will soon lift the pause in order to continue towards attaining herd immunity. In all, only about one in every million doses of Johnson & Johnson’s vaccine resulted in the rare blood clots so far.
JNJ Stock dividend
Johnson & Johnson is set to report its Q1 earnings report on Tuesday, and investors have no reason to believe it won’t be another stellar quarter from one of the largest companies in the world. JNJ currently pays a generous 2.49% dividend yield to shareholders, and with over 50 consecutive years of the company raising its dividends, it represents one of the best long-term investments available to investors.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.